CO2017004596A2 - Formulación estable de proteina en solucion que contiene una alta concentracion de un anticuerpo anti-vegf - Google Patents

Formulación estable de proteina en solucion que contiene una alta concentracion de un anticuerpo anti-vegf

Info

Publication number
CO2017004596A2
CO2017004596A2 CONC2017/0004596A CO2017004596A CO2017004596A2 CO 2017004596 A2 CO2017004596 A2 CO 2017004596A2 CO 2017004596 A CO2017004596 A CO 2017004596A CO 2017004596 A2 CO2017004596 A2 CO 2017004596A2
Authority
CO
Colombia
Prior art keywords
high concentration
solution containing
vegf antibody
antibody
protein formulation
Prior art date
Application number
CONC2017/0004596A
Other languages
English (en)
Spanish (es)
Inventor
Huixiang Zhang
Charles Boring
Alok Kulshreshtha
Yuhong Zeng
Li Wan
Laman Alani
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54697654&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO2017004596(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CO2017004596A2 publication Critical patent/CO2017004596A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B3/00—Apparatus for testing the eyes; Instruments for examining the eyes
    • A61B3/10—Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions
    • A61B3/12—Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions for looking at the eye fundus, e.g. ophthalmoscopes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4848—Monitoring or testing the effects of treatment, e.g. of medication
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medical Informatics (AREA)
  • Surgery (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CONC2017/0004596A 2014-11-07 2017-05-05 Formulación estable de proteina en solucion que contiene una alta concentracion de un anticuerpo anti-vegf CO2017004596A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462076770P 2014-11-07 2014-11-07
US201462088061P 2014-12-05 2014-12-05
PCT/US2015/059571 WO2016073915A1 (en) 2014-11-07 2015-11-06 Stable protein solution formulation containing high concentration of an anti-vegf antibody

Publications (1)

Publication Number Publication Date
CO2017004596A2 true CO2017004596A2 (es) 2017-08-31

Family

ID=54697654

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2017/0004596A CO2017004596A2 (es) 2014-11-07 2017-05-05 Formulación estable de proteina en solucion que contiene una alta concentracion de un anticuerpo anti-vegf

Country Status (24)

Country Link
US (5) US10689438B2 (enExample)
EP (2) EP3215122B1 (enExample)
JP (6) JP6753848B2 (enExample)
KR (4) KR20170082526A (enExample)
CN (4) CN114081951A (enExample)
AU (6) AU2015342815B2 (enExample)
BR (2) BR112017008093A2 (enExample)
CA (2) CA2966646A1 (enExample)
CL (2) CL2017001117A1 (enExample)
CO (1) CO2017004596A2 (enExample)
EA (1) EA201790989A1 (enExample)
EC (1) ECSP17034829A (enExample)
GT (1) GT201700096A (enExample)
IL (5) IL251642B (enExample)
MX (3) MX383808B (enExample)
MY (2) MY183807A (enExample)
NZ (1) NZ730821A (enExample)
PE (1) PE20170780A1 (enExample)
PH (3) PH12021550147A1 (enExample)
RU (1) RU2722643C2 (enExample)
SG (3) SG10201913565RA (enExample)
TN (1) TN2017000128A1 (enExample)
TW (4) TWI806150B (enExample)
WO (2) WO2016073915A1 (enExample)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2473565C2 (ru) 2006-04-07 2013-01-27 Аерпио Терапетикс, Инк. АНТИТЕЛА, СВЯЗЫВАЮЩИЕ ТИРОЗИН ФОСФАТАЗУ БЕТА ЧЕЛОВЕКА (HPTPβ), И ИХ ИСПОЛЬЗОВАНИЕ
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
SI2307458T1 (en) 2008-06-25 2018-08-31 Esbatech, An Alcon Biomedical Research Unit Llc Humanization of rabbit antibodies using a universal antibody framework
ES2861592T3 (es) 2008-06-25 2021-10-06 Novartis Ag Anticuerpos estables y solubles que inhiben el TNF
CN105412094A (zh) 2009-07-06 2016-03-23 爱尔皮奥治疗有限公司 用于防止癌细胞转移的化合物、组合物和方法
EP3763379A1 (en) 2011-01-13 2021-01-13 Regeneron Pharmaceuticals, Inc. Use of a vegf antagonist to treat angiogenic eye disorders
MX363351B (es) 2011-10-13 2019-03-20 Aerpio Therapeutics Inc Un agente de unión a hptp?-ecd para usarse en el tratamiento de síndrome de fuga vascular.
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
JP6483148B2 (ja) 2014-03-14 2019-03-13 エアーピオ セラピューティクス インコーポレイテッド ＨＰＴＰ−β阻害剤
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
TWI806150B (zh) 2014-11-07 2023-06-21 瑞士商諾華公司 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物
EP3250596A1 (en) 2015-01-28 2017-12-06 Pfizer Inc Stable aqueous anti- vascular endothelial growth factor (vegf) antibody formulation
US10464999B2 (en) 2015-01-28 2019-11-05 Prothena Biosciences Limited Anti-transthyretin antibodies
US9879080B2 (en) 2015-01-28 2018-01-30 Prothena Biosciences Limited Anti-transthyretin antibodies
US10633433B2 (en) 2015-01-28 2020-04-28 Prothena Biosciences Limited Anti-transthyretin antibodies
EP3977994B1 (en) 2015-09-23 2024-04-24 EyePoint Pharmaceuticals, Inc. Activators of tie-2 for use in treating intraocular pressure
BR112018011089A2 (pt) 2015-12-04 2018-12-04 Intellia Therapeutics Inc composições e métodos para a imuno-oncologia
WO2017117464A1 (en) 2015-12-30 2017-07-06 Kodiak Sciences Inc. Antibodies and conjugates thereof
US10253094B2 (en) 2016-07-20 2019-04-09 Aerpio Therapeutics, Inc. Antibodies that target human protein tyrosine phosphatase-beta (HPTP-beta) and methods of use thereof to treat ocular conditions
AU2017324983B2 (en) * 2016-09-07 2025-03-20 Saksin Lifesciences Pvt Ltd Synthetic antibodies against VEGF and their uses
EP3518971A4 (en) * 2016-09-28 2020-05-13 Board Of Regents, The University Of Texas System Antibody and protein therapeutic formulations and uses thereof
KR102512833B1 (ko) 2016-11-18 2023-03-23 아스텔라스세이야쿠 가부시키가이샤 신규 항인간 MUC1 항체 Fab 프래그먼트
JP2020513832A (ja) 2017-03-22 2020-05-21 ノバルティス アーゲー 免疫腫瘍学のための組成物および方法
JOP20190245A1 (ar) 2017-04-20 2019-10-15 Novartis Ag أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
CN109562166B (zh) * 2017-04-28 2021-04-02 苏州思坦维生物技术股份有限公司 一种眼用药物组合物及其用途
TWI795415B (zh) 2017-07-07 2023-03-11 日商安斯泰來製藥股份有限公司 新穎的抗人類ＣＥＡＣＡＭ５抗體Ｆａｂ片段
WO2019020777A1 (en) * 2017-07-26 2019-01-31 Formycon Ag LIQUID FORMULATION OF A VEGF ANTAGONIST
KR102581734B1 (ko) 2017-10-06 2023-09-22 네오토프 뉴로사이언스 리미티드 트랜스타이레틴의 검출 방법
BR112020006434A2 (pt) 2017-10-06 2020-11-03 Prothena Biosciences Limited anticorpos anti-transtirretina
BR112020010483A2 (pt) * 2017-11-29 2020-10-20 Prothena Biosciences Limited formulação liofilizada de um anticorpo monoclonal contra transtirretina
CN111465407A (zh) 2017-11-30 2020-07-28 瑞泽恩制药公司 使用vegf拮抗剂治疗生血管性眼病
MX2020007527A (es) * 2018-02-06 2020-09-09 Hoffmann La Roche Tratamiento de enfermedades oftalmologicas.
BR112020017872A2 (pt) 2018-03-02 2020-12-22 Kodiak Sciences Inc. Anticorpos de il-6 e construtos de fusão e conjugados dos mesmos
WO2019175727A1 (en) * 2018-03-16 2019-09-19 Novartis Ag Methods for treating ocular diseases
AU2019237252A1 (en) * 2018-03-23 2020-10-22 AbbVie Deutschland GmbH & Co. KG Stable aqueous anti-tau antibody formulations
EP3775267A4 (en) * 2018-04-10 2022-05-18 Askgene Pharma, Inc. NOVEL ANGIOPOIETIN-2, VEGF DUAL ANTAGONISTS
JOP20200275A1 (ar) 2018-05-10 2020-11-02 Regeneron Pharma صيغ تحتوي على بروتين اندماج لمستقبلvegf مرتفعة التركيز
BR112020023420A8 (pt) 2018-05-17 2022-07-05 Astellas Pharma Inc Complexo tendo fragmento fab de anticorpo anti-muc1 humano, peptídeo ligador e/ou ligante
CN113164597B (zh) 2018-09-24 2025-02-28 视点制药公司 靶向HPTP-β（VE-PTP）和VEGF的多特异性抗体
TW202027794A (zh) 2018-10-03 2020-08-01 瑞士商諾華公司 血管生成素樣３多肽之持續遞送
EP3865154A4 (en) 2018-10-10 2022-11-09 Astellas Pharma Inc. PHARMACEUTICAL COMPOSITION CONTAINING ANTIBODY FAB FRAGMENT COMPLEX AT LABELED ANTI-HUMAN SITE
CN119033684A (zh) * 2018-10-29 2024-11-29 豪夫迈·罗氏有限公司 抗体制剂
IL282986B2 (en) 2018-11-07 2024-01-01 Applied Molecular Transport Inc Colics-derivative carriers for oral administration of heterologous cargo
TWI857996B (zh) * 2018-12-18 2024-10-11 瑞士商諾華公司 含高濃度抗ｖｅｇｆ抗體之蛋白質溶液配製物
JOP20210229A1 (ar) 2019-02-18 2023-01-30 Lilly Co Eli صيغة جسم مضاد علاجي
TWI862583B (zh) 2019-04-26 2024-11-21 美商愛德維仁生物科技公司 用於玻璃體內遞送之變異體aav蛋白殼
CN114269341A (zh) 2019-04-29 2022-04-01 视点制药公司 靶向施莱姆管的Tie-2激活剂
CA3150859A1 (en) 2019-08-16 2021-02-25 Applied Molecular Transport Inc. Compositions, formulations, and interleukin production and purification
CA3157509A1 (en) * 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
CN111217834B (zh) * 2020-02-21 2021-10-26 维眸生物科技（上海）有限公司 Rock激酶抑制剂的硝基氧衍生物
EP4115903A4 (en) * 2020-03-04 2023-12-20 Shanghai Henlius Biotech, Inc. Pharmaceutical formulation comprising bevacizumab
CN113698478B (zh) * 2020-05-21 2025-11-18 迈威(上海)生物科技股份有限公司 抗α-溶血素的抗体及其稳定制剂
KR20220001106A (ko) * 2020-06-29 2022-01-05 (주)메디톡스 고농도 항-ｖｅｇｆ 항체 제제 및 이에 사용하기 위한 항-ｖｅｇｆ 항체
PE20231093A1 (es) 2020-07-16 2023-07-18 Novartis Ag Anticuerpos anti-betacelulina, fragmentos de los mismos, y moleculas de union multiespecificas
DK4185318T3 (da) * 2021-05-17 2025-09-29 Regeneron Pharma Forlængede, højdosis-VEGF-antagonistregimer til behandling af angiogene øjensygdomme
CN113940997B (zh) * 2021-12-21 2022-04-08 迈威(上海)生物科技股份有限公司 一种双特异性抗体的稳定制剂
KR20250065646A (ko) * 2022-09-16 2025-05-13 치루 파머수티컬 컴퍼니 리미티드 안정적인 고농도 자가완충식 약물 조성물
WO2025231345A1 (en) * 2024-05-03 2025-11-06 Therini Bio, Inc. Doses of antibodies which bind human fibrin yc or fibrinogen yc domain for ocular diseases

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
EP2319492A3 (en) 2004-10-21 2011-08-10 Genentech, Inc. Method for treating intraocular neovascular diseases
WO2007011873A2 (en) * 2005-07-15 2007-01-25 Genentech, Inc. Method for treating intraocular neovascular diseases
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
PT2944306T (pt) * 2006-06-16 2021-02-15 Regeneron Pharma Formulações antagonistas de vegf adequadas para administração intravitreal
PE20090329A1 (es) 2007-05-30 2009-03-27 Abbott Lab Anticuerpos humanizados contra el globulomero ab(20-42) y sus usos
TWI468417B (zh) 2007-11-30 2015-01-11 Genentech Inc 抗－ｖｅｇｆ抗體
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
SI2307458T1 (en) 2008-06-25 2018-08-31 Esbatech, An Alcon Biomedical Research Unit Llc Humanization of rabbit antibodies using a universal antibody framework
DK2307454T3 (en) * 2008-06-25 2017-04-24 Esbatech Alcon Biomed Res Unit Stable and soluble antibodies that inhibit VEGF
ES2861592T3 (es) 2008-06-25 2021-10-06 Novartis Ag Anticuerpos estables y solubles que inhiben el TNF
JP5988580B2 (ja) 2008-06-30 2016-09-07 エスバテック − ア ノバルティス カンパニー エルエルシー 機能性ポリペプチド
AR079556A1 (es) 2009-12-21 2012-02-01 Genentech Inc Formacion de anticuerpos
US9458240B2 (en) 2010-12-10 2016-10-04 Novartis Pharma Ag Anti-BAFFR antibody formulations
EP3763379A1 (en) * 2011-01-13 2021-01-13 Regeneron Pharmaceuticals, Inc. Use of a vegf antagonist to treat angiogenic eye disorders
AU2012275233A1 (en) * 2011-06-30 2013-11-28 Genentech, Inc. Anti-c-met antibody formulations
KR20140082700A (ko) * 2011-10-20 2014-07-02 에스바테크 - 어 노바티스 컴파니 엘엘씨 안정적인 다중 항원-결합 항체
JP6720443B2 (ja) 2012-05-03 2020-07-08 カラ ファーマシューティカルズ インコーポレイテッド 改善された粘膜輸送を示す医薬用ナノ粒子
US20140004131A1 (en) 2012-05-04 2014-01-02 Novartis Ag Antibody formulation
US9216219B2 (en) 2012-06-12 2015-12-22 Novartis Ag Anti-BAFFR antibody formulation
JOP20200175A1 (ar) 2012-07-03 2017-06-16 Novartis Ag حقنة
UA117466C2 (uk) * 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
MY189047A (en) 2013-03-13 2022-01-21 Genentech Inc Antibody formulations
WO2015086830A1 (en) * 2013-12-13 2015-06-18 Delenex Therapeutics Ag Skin penetrating polypeptides
US9388239B2 (en) 2014-05-01 2016-07-12 Consejo Nacional De Investigation Cientifica Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B
RU2017101236A (ru) * 2014-06-17 2018-07-17 Клиасайд Байомедикал, Инк. Способы и устройства для лечения патологических нарушений в заднем сегменте глаза
TWI806150B (zh) 2014-11-07 2023-06-21 瑞士商諾華公司 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物
US20160144025A1 (en) 2014-11-25 2016-05-26 Regeneron Pharmaceuticals, Inc. Methods and formulations for treating vascular eye diseases
WO2019175727A1 (en) 2018-03-16 2019-09-19 Novartis Ag Methods for treating ocular diseases
TWI857996B (zh) 2018-12-18 2024-10-11 瑞士商諾華公司 含高濃度抗ｖｅｇｆ抗體之蛋白質溶液配製物

Also Published As

Publication number Publication date
MX2021006768A (es) 2021-07-15
AU2020244614B2 (en) 2023-06-01
IL265497B (en) 2021-06-30
JP2022141923A (ja) 2022-09-29
IL251642B (en) 2021-02-28
US20160130337A1 (en) 2016-05-12
BR112017008660A2 (pt) 2017-12-26
CN120938921A (zh) 2025-11-14
MY183807A (en) 2021-03-16
US11098110B2 (en) 2021-08-24
AU2020244614A1 (en) 2020-11-05
AU2018274882A1 (en) 2018-12-20
MX383808B (es) 2025-03-14
IL283561A (en) 2021-07-29
EA201790989A1 (ru) 2017-09-29
KR20170082526A (ko) 2017-07-14
BR112017008093A2 (pt) 2018-03-13
AU2015342815B2 (en) 2018-12-13
AU2015342818A1 (en) 2017-05-11
IL283561B (en) 2022-01-01
SG11201702909QA (en) 2017-05-30
US10689438B2 (en) 2020-06-23
TW202103735A (zh) 2021-02-01
KR102724014B1 (ko) 2024-10-31
TW201625221A (zh) 2016-07-16
IL251696A0 (en) 2017-06-29
CL2017001115A1 (es) 2018-01-26
IL280087B (en) 2022-02-01
TWI761959B (zh) 2022-04-21
KR20230066649A (ko) 2023-05-16
TWI705827B (zh) 2020-10-01
EP3215123A1 (en) 2017-09-13
RU2017119647A (ru) 2018-12-07
PH12017500844B1 (en) 2021-05-05
US20210340242A1 (en) 2021-11-04
RU2017119647A3 (enExample) 2019-05-29
MY193913A (en) 2022-11-01
JP2020079242A (ja) 2020-05-28
EP3215122A1 (en) 2017-09-13
JP6667519B2 (ja) 2020-03-18
RU2722643C2 (ru) 2020-06-02
US10035850B2 (en) 2018-07-31
CA2966758A1 (en) 2016-05-12
CL2017001117A1 (es) 2018-01-26
AU2015342815A1 (en) 2017-05-11
AU2018278870A1 (en) 2019-01-03
CN114081951A (zh) 2022-02-25
MX383399B (es) 2025-03-13
KR102588846B1 (ko) 2023-10-16
PH12017500844A1 (en) 2017-10-30
AU2020220210B2 (en) 2022-01-20
PH12021550147A1 (en) 2023-01-23
KR20240161204A (ko) 2024-11-12
KR20170076781A (ko) 2017-07-04
US20160340420A1 (en) 2016-11-24
CN107635580A (zh) 2018-01-26
TW201625306A (zh) 2016-07-16
SG10201913565RA (en) 2020-02-27
CA2966646A1 (en) 2016-05-12
JP2017534638A (ja) 2017-11-24
PE20170780A1 (es) 2017-07-04
AU2018274882B2 (en) 2020-07-09
AU2018278870B2 (en) 2020-05-28
JP2025004075A (ja) 2025-01-14
US12049495B2 (en) 2024-07-30
JP6753848B2 (ja) 2020-09-09
MX2017005875A (es) 2017-06-26
WO2016073918A1 (en) 2016-05-12
US20200270336A1 (en) 2020-08-27
RU2020114917A (ru) 2020-05-22
JP2017538674A (ja) 2017-12-28
EP3215122B1 (en) 2025-08-13
IL265497A (en) 2019-05-30
US20180298092A1 (en) 2018-10-18
ECSP17034829A (es) 2019-02-28
MX2017005874A (es) 2017-06-26
TWI806150B (zh) 2023-06-21
TWI738632B (zh) 2021-09-11
EP3215122C0 (en) 2025-08-13
IL280087A (en) 2021-03-01
TN2017000128A1 (en) 2018-10-19
AU2015342818B2 (en) 2019-01-03
AU2020220210A1 (en) 2020-10-01
TW202146049A (zh) 2021-12-16
JP2020193212A (ja) 2020-12-03
WO2016073915A1 (en) 2016-05-12
SG11201702954XA (en) 2017-05-30
IL251642A0 (en) 2017-06-29
NZ730821A (en) 2019-11-29
CN106999581A (zh) 2017-08-01
PH12017500843A1 (en) 2017-10-30
GT201700096A (es) 2019-10-10
RU2020114917A3 (enExample) 2022-01-17
US12371481B2 (en) 2025-07-29
JP7080263B2 (ja) 2022-06-03

Similar Documents

Publication Publication Date Title
CO2017004596A2 (es) Formulación estable de proteina en solucion que contiene una alta concentracion de un anticuerpo anti-vegf
CY1122181T1 (el) Φαρμακοτεχνικη μορφη αντισωματος
CO7111300A2 (es) Formulación de anticuerpos
AR107014A1 (es) Formulación farmacéutica acuosa
CL2018003178A1 (es) Composición farmacéutica
BR112016026811A2 (pt) formulação de anticorpo
BR112015022210A2 (pt) formulações farmacêuticas aquosas estáveis, seu uso, artigo de manufatura, métodos de redução da agregação de um anticorpo monoclonal terapêutico e método de produção de uma formulação farmacêutica.
CL2021001587A1 (es) Formulación de solución de proteínas que contiene una alta concentración de un anticuerpo anti-vegf
AR091530A1 (es) Formulacion farmaceutica liquida de un anticuerpo y acetato
AR130115A2 (es) Formulación de solución de proteína estable que contiene alta concentración de un anticuerpo anti-vegf
AR102572A1 (es) Formulación de solución de proteína estable que contiene alta concentración de un anticuerpo anti-vegf